title: Modifications in relaxin's serum levels during acetate-free biofiltration (AFB): only a new biomarker?
abstract: OBJECTIVE
  We evaluated relaxin's behaviour during a haemodialytic session and the effects of its intradialytic variability on blood pressure.
  
  
  METHODS
  We enrolled 25 patients and evaluated relaxin's levels during a haemodialytic session. We also dosed interdialytic relaxin and enrolled 10 healthy subjects and 16 patients with III stage chronic renal failure as controls.
  
  
  RESULTS
  Haemodialyzed patients have relaxin's baseline concentrations higher than healthy controls, but lower than chronic patients. During the treatment, relaxin is removed; it increases again throughout the interdialytic phase. Furthermore, relaxin's pre- haemodialytic concentration positively and significantly correlates with systolic, diastolic, and mean BP; such correlations disappear at the end of the treatment.
  
  
  CONCLUSIONS
  Relaxin's removal during the treatment may intervene in the pathogenesis of intradialytic hypertension. Hence, relaxin could be not only a new biomarker but also an active player in the intradialytic variations of blood pressure.
authors.forename: Valeria
authors.initials: V
authors.lastname: Cernaro
authors.forename: Antonio
authors.initials: A
authors.lastname: Lacquaniti
authors.forename: Grazia
authors.initials: G
authors.lastname: Giorgianni
authors.forename: Davide
authors.initials: D
authors.lastname: Bolignano
authors.forename: Michele
authors.initials: M
authors.lastname: Buemi
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D017583:Hemodiafiltration; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012065:Relaxin / Q000097:blood* / Q000627:therapeutic use*; D006435:Renal Dialysis
chemical_list: D015415:Biomarkers; D012065:Relaxin